Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF
An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Vnitřnı lékařství - 61(2015), 5, Seite 470 |
| Sprache: |
Tschechisch |
|---|
| Beteiligte Personen: |
Vítovec, Jiří [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1962135381 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1962135381 | ||
| 003 | DE-627 | ||
| 005 | 20230508123452.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1962135381 | ||
| 035 | |a (DE-599)GBVOLC1962135381 | ||
| 035 | |a (PRQ)pubmed_primary_260758580 | ||
| 035 | |a (KEY)N0524285420150000061000500470inhibitionofreninangiotensinaldosteronesysteminhea | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Vítovec, Jiří |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure. | ||
| 650 | 4 | |a Renin-Angiotensin System - drug effects | |
| 650 | 4 | |a Heart Failure - drug therapy | |
| 650 | 4 | |a Heart Failure - metabolism | |
| 650 | 4 | |a Angiotensin-Converting Enzyme Inhibitors - therapeutic use | |
| 650 | 4 | |a Angiotensin Receptor Antagonists - therapeutic use | |
| 700 | 1 | |a Špinar, Jindřich |4 oth | |
| 700 | 1 | |a Špinarová, Lenka |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Vnitřnı lékařství |d Praha : Česká Lékařská Společnost Jana Evangelisty Purkyně, 1955 |g 61(2015), 5, Seite 470 |w (DE-627)166267376 |w (DE-600)138213-5 |w (DE-576)014611228 |x 0042-773X |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2015 |g number:5 |g pages:470 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26075858 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2015 |e 5 |h 470 | ||